AZ's PD-L1 shows efficacy in NSCLC, melanoma

Abstracts released in advance of the American Society of Clinical Oncology (ASCO) meeting featured data from multiple studies of MEDI4736 from AstraZeneca plc (LSE:AZN; NYSE:AZN), including efficacy data in studies to treat non-small cell lung cancer (NSCLC) and advanced melanoma. MEDI4736 is a human IgG1 mAb targeting PD-L1.

In an ongoing Phase Ib dose-escalation study to treat NSCLC, MEDI4736 plus tremelimumab led to partial responses in eight (26%) of 31 evaluable patients and stable disease in 11 (35%). Overall, 18% of patients discontinued treatment due to drug-related adverse events. A maximum tolerated dose has not yet been defined. ...